<DOC>
	<DOCNO>NCT02433626</DOCNO>
	<brief_summary>Activity COTI-2 demonstrate OVCAR-3 ovarian cancer tumor model . With p53- AKT-based mechanism action , COTI-2 anticipate highly relevant treatment patient gynecologic malignancy . This study design primarily assess safety tolerability COTI-2 patient advance recurrent gynecologic head neck malignancy establish recommend Phase 2 dose ( RP2D ) future study .</brief_summary>
	<brief_title>A Study Coti-2 Treatment Advanced Recurrent Gynecologic Malignancies</brief_title>
	<detailed_description>This single arm , single center , open-label , Phase 1 , first time human study COTI-2 patient recurrent ovarian , fallopian tube , primary peritoneal cancer , endometrial , cervical head neck cancer . COTI-2 self-administered single agent , orally , daily 5 day follow 2 treatment-free day week .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . ≥18 year age . 2 . Willing able provide write informed consent participate investigational study . 3 . Cancer recurrent , metastatic , unresectable effective curative measure exist . Part 1 : Ovarian , fallopian tube , primary peritoneal , endometrial , cervical cancer Part 2 : Ovarian HNSCC , histologically confirm p53 mutation 4 . Ability attend schedule study visit 5 . Measurable disease physical examination imaging define RECIST v1.1 criterion evaluable disease define Gynecologic Cancer Intergroup ( GCIG ) CA125 criterion . 6 . European Cooperative Oncology Group ( ECOG ) performance status 0 1 . 7 . Life expectancy ≥3 month . 8 . Adequate bone marrow , liver , renal , cardiac function study entry , assess follow : Hemoglobin ≥9.0 g/dL ; Absolute neutrophil count ( ANC ) ≥1.5 x 109/L ; Platelet count ≥100 x 109/L ; Prothrombin time ( PT ) international normalize rate ( INR ) within normal limit ; Partial thromboplastin time ( PTT ) within normal limit ; Total bilirubin within normal limit ; Alanine transaminase ( ALT ) aspartate transaminase ( AST ) within normal limit ; Calculated creatinine clearance &gt; 50 mL/min ; Urine protein &lt; 500 mg urine protein : creatinine ratio ( UPC ) &lt; 1.0 ; Left ventricular ejection fraction ( LVEF ) ≥55 % ( institutional low limit normal [ LLN ] ) evidence ECHO . 9 . Prior chemotherapy , investigational agent , radiation must discontinue least 28 day prior first administration COTI2 . Hormone treatment must discontinue least 28 day prior first administration COTI2 . 10 . Toxicity prior therapy ( except alopecia ) resolve ≤Grade 1 ; event toxicity resolve ≤Grade 1 consider stable , patient may eligible discussion among investigator sponsor 's medical monitor . 11 . Physiologically incapable become pregnant , postmenopausal , negative pregnancy test agree use adequate contraception ( e.g. , oral contraceptive , double barrier method , intrauterine device , intramuscular contraceptive ) . 12 . Patients enrolled expansion phase must willing undergo pre postCycle 1 biopsy . 13 . Patients enrolled escalation expansion phase require archival tissue available analysis . 1 . Pregnant lactating . 2 . History invasive malignancy , exception nonmelanoma skin cancer successfully treat situ carcinoma , evidence malignancy present within last 3 year . 3 . Inability tolerate oral medication . 4 . Any serious and/or unstable preexist medical , psychiatric , condition ( e.g. , severe hepatic impairment ) current unstable uncompensated respiratory cardiac condition make undesirable patient participate study could jeopardize compliance protocol . 5 . History clinically significant uncontrolled cardiac disease include limited : 1 . Myocardial infarction , 2 . Angina pectoris , 3 . Congestive heart failure New York Heart Association ( NYHA ) Grade &gt; 2 , 4 . Ventricular arrhythmia require continuous therapy , 5 . Supraventricular arrhythmia include atrial fibrillation , uncontrolled . 6 . Major surgery , exclude skin biopsy procedures insertion central venous access device , within 28 day prior start COTI2 . 7 . Active , uncontrolled bacterial , viral , fungal , opportunistic infection require systemic therapy . 8 . Part 2 : 1 . The presence imminent occurrence airway obstruction , unless tracheostomy place . 2 . HPVpositive status ( In HNSCC patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>